- ►diabetesjournals.org M Zander, A Christiansen, S Madsbad, J Juul Holst - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—Fasting plasma glucose decreased from 13.5 ± 1.2 mmol/l (saline) to 11.7 ± 1.2 (GLP-1)
and 11.5 ± 1.2 (pioglitazone) and further decreased to 9.9 ± 1.0 (combination) (P < 0.001).
Eight-hour mean plasma glucose ... Cited by 20 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org M Zander, M Taskiran, MB Toft-Nielsen, S Madsbad … - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE—The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma glucose in type 2
diabetic patients by stimulating insulin secretion and inhibiting glucagon secretion. The biguanide
metformin is believed to lower ... Cited by 47 - Related articles - BL Direct - All 7 versions
MT Behme, J Dupré, TJ McDonald - BMC Endocrine Disorders, 2003 - biomedcentral.com Dose-finding studies were carried out to establish mid range doses for delay of gastric emptying
indicated by postponement of pancreatic polypeptide responses after meals. The selected dose of 0.63
micrograms/kg GLP-1 was ... Cited by 30 - Related articles - Cached - All 7 versions
- ►endojournals.org J Dupre, MT Behme, TJ McDonald - Journal of Clinical Endocrinology & …, 2004 - Endocrine Soc Exendin-4 is a reptilian peptide that activates the mammalian receptor for truncated glucagon-like
peptide 1 (tGLP-1) with relatively prolonged actions. Exendin-4 and tGLP-1 can reduce blood glucose
levels by stimulating insulin ... Cited by 48 - Related articles - All 4 versions
U Ribel, MO Larsen, B Rolin, RD Carr, M Wilken, J … - European journal of …, 2002 - Elsevier Glucagon-like peptide-1 (GLP-1) is an effective anti-diabetic agent, but its metabolic instability
makes it therapeutically unsuitable. This study investigated the pharmacodynamics of a long-acting
GLP-1 derivative (NN2211: (Arg 34 ... Cited by 43 - Related articles - All 4 versions
- ►diabetesjournals.org GS Meneilly, CHS McIntosh, RA Pederson, JF … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Plasma glucose was allowed to fall from a fasting level of ∼11 mmol/l to 5.3 mmol/l in
each study and thereafter was held stable at that level. Plasma insulin levels during both studies
were ∼900 pmol/l. Plasma ... Cited by 20 - Related articles - BL Direct - All 5 versions
GS Meneilly, N Greig, H Tildesley, JF Habener, JM … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 16 patients with type 2 diabetes who were being treated
with oral hypoglycemic agents were enrolled. Eight patients (aged 75 ± 2 years, BMI 27 ± 1 kg/m 2
) remained on usual ... Cited by 58 - Related articles - BL Direct - All 9 versions
- ►endojournals.org JP Gutzwiller, S Tschopp, A Bock, CE Zehnder, … - Journal of Clinical …, 2004 - Endocrine Soc Glucagon-like peptide-1-(7–36)-amide (GLP-1) is involved in satiety control and glucose
homeostasis. Animal studies suggest a physiological role for GLP-1 in water and salt homeostasis.
This study's aim was to define the ... Cited by 33 - Related articles - BL Direct - All 4 versions
N Mikhail - Southern Medical Journal, 2006 - pdfs.journals.lww.com Abstract: Exenatide (synthetic exendin-4) is the analog of gluca- gon-like peptide 1 (GLP-1), the
major physiologic incretin. The latter is an intestinal hormone that enhances glucose-induced
insulin secretion after meals. In ... Cited by 6 - Related articles - BL Direct - All 5 versions
[CITATION] Evidence for insulin independent suppression of glucagon secretion by LAF237
